SCHEDULE: Lipella Pharmaceuticals Inc. Shareholder Update: Michael B. Chancellor's Ownership Adjusted After Reverse Stock Split

Michael B. Chancellor updates his beneficial ownership in Lipella Pharmaceuticals to 11.5% following a reverse stock split and adjustments to his holdings.

Summary

• This document is an amendment to a Schedule 13D filing by Michael B. Chancellor regarding his ownership in Lipella Pharmaceuticals Inc.
• The amendment reflects changes due to a 1-for-8 reverse stock split that Lipella Pharmaceuticals implemented on November 7, 2024.
• As of this filing, Michael B. Chancellor beneficially owns 209,640 shares of common stock, representing 11.5% of the outstanding shares.
• This ownership includes 109,703 shares purchased with personal funds and 99,937 shares issuable upon the exercise of vested stock options.
• The total number of outstanding shares used for this calculation is 1,719,222, as verified with the Issuer.

Sentiment

Score: 7

Explanation: The document is a routine regulatory filing with no significant positive or negative implications. It reflects a necessary update due to a corporate action.

Positives

• The document provides a clear update on Michael B. Chancellor's ownership stake in Lipella Pharmaceuticals.
• The filing is transparent about the impact of the reverse stock split on share numbers.
• The document confirms the source of funds for the shares owned by Michael B. Chancellor.

Risks

• The document does not explicitly mention any risks, but changes in ownership percentages can sometimes indicate shifts in investor sentiment or strategic direction.
• The reverse stock split could be a sign of financial difficulties or an attempt to maintain listing requirements.

Industry Context

Schedule 13D filings are a standard part of regulatory compliance for significant shareholders in publicly traded companies, and this filing is a routine update reflecting changes in ownership due to a corporate action (reverse stock split).

Comparison to Industry Standards

• Schedule 13D filings are common for investors holding more than 5% of a company's shares, and this filing is consistent with regulatory requirements.
• Reverse stock splits are often used by companies to increase their share price and maintain listing requirements, which is a common practice in the pharmaceutical industry.
• The ownership percentage of 11.5% is not unusual for a significant shareholder, especially one who is also an officer and director of the company.

Stakeholder Impact

• The update provides transparency to shareholders regarding Michael B. Chancellor's ownership stake.
• The reverse stock split may have an impact on the perceived value of the shares for all shareholders.

Key Dates

Keywords

Lipella Pharmaceuticals, Michael B. Chancellor, Schedule 13D, Beneficial Ownership, Reverse Stock Split, Stock Options, Shareholder